专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018189020A2 METHODS FOR IDENTIFYING PRE-DISPOSITION TO COGNITIVE DECLINE AND AGENTS FOR REDUCING OR PREVENTING COGNITIVE DECLINE, OR IMPROVING COGNITIVE ABILITY 审中-公开
公开(公告)号：WO2018189020A2
公开(公告)日：2018-10-18
申请号：PCT/EP2018/058701
申请日：2018-04-05
申请人： NESTEC S.A.
发明人： BOWMAN, Gene , HUDRY-LABBE, Julie , SCHMITT, Jeroen Antonius Johannes , BOSCHAT, Corina , RIEKER, Claus
IPC分类号： A61K31/202 , A61P25/28 , A61K31/14 , A61K31/4415 , A61K31/51 , A61K31/592 , A61K31/593
CPC分类号： A61K31/198 , A61K31/14 , A61K31/202 , A61K31/4415 , A61K31/51 , A61K31/592 , A61K31/593 , A61K31/714 , A61P25/28 , A61K2300/00
摘要： A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

2. 发明申请

WO2018060396A1 OMEGA 3 FATTY ACIDS AND CHOLINE AS NEUROPROTECTANT IN PATIENTS WITH NO DEMENTIA 审中-公开
标题翻译： OMEGA 3脂肪酸和胆碱作为神经保护剂在无痴呆病人中的应用
公开(公告)号：WO2018060396A1
公开(公告)日：2018-04-05
申请号：PCT/EP2017/074731
申请日：2017-09-29
申请人： NESTEC S.A.
发明人： RIEKER, Claus , HUDRY-LABBE, Julie , SCHMITT, Jeroen Antonius Johannes , BOSCHAT, Corina , SILBER, Yvonne Beata
IPC分类号： A61K31/202 , A61P25/28 , A61K31/14
摘要： A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid and choline. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-β phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human. The composition can be administered to the individual in a daily dose that provides 5.5 mg/day to 5,500 mg/day of the choline, for example 85 mg/day to 3,500 mg/day of the choline.
摘要翻译：减轻，治疗或预防没有痴呆的个体的认知衰老的方法包括向个体施用治疗有效量的含有ω-3脂肪酸和胆碱的组合物。该方法可以实现减少脑萎缩，增加或维持突触数量，增加淀粉样蛋白-β吞噬作用，或减少或维持非痴呆个体的神经炎症中的一种或多种益处。该方法可以预防有风险的个体，例如老年人的痴呆。该组合物可以以提供5.5mg /天至5,500mg /天的胆碱，例如85mg /天至3,500mg /天的胆碱的日剂量给予个体。

3. 发明申请

WO2018189020A3 OMEGA-3 FATTY ACID, HOMOCYSTEIN AND VITAMIN D LEVELS TO IDENTIFY AND ATTENUATE COGNITIVE AGING IN INDIVIDUALS 审中-公开
公开(公告)号：WO2018189020A3
公开(公告)日：2018-10-18
申请号：PCT/EP2018/058701
申请日：2018-04-05
申请人： NESTEC S.A.
发明人： BOWMAN, Gene , HUDRY-LABBE, Julie , SCHMITT, Jeroen Antonius Johannes , BOSCHAT, Corina , RIEKER, Claus
IPC分类号： A61K31/202 , A61P25/28 , A61K31/14 , A61K31/4415 , A61K31/51 , A61K31/592 , A61K31/593
摘要： A method for identifying pre-disposition to cognitive decline in a subject, the method comprising determining levels of: (a) omega-3 fatty acids, and vitamin D or a metabolite thereof; (b) omega-3 fatty acids, and homocysteine; (c) vitamin D or a metabolite thereof, and homocysteine; or (d) omega-3 fatty acids, vitamin D or a metabolite thereof, and homocysteine, independently in one or more samples obtained from the subject.

4. 发明申请

WO2018060395A1 OMEGA 3 FATTY ACIDS, NO RELEASING COMPOUND AND VITAMIN B12 AS NEUROPROTECTANT IN PATIENTS WITH NO DEMENTIA 审中-公开
标题翻译： OMEGA 3脂肪酸，不释放化合物和维生素B12作为神经保护剂在无痴呆病人中的应用
公开(公告)号：WO2018060395A1
公开(公告)日：2018-04-05
申请号：PCT/EP2017/074729
申请日：2017-09-29
申请人： NESTEC S.A.
发明人： SILBER, Yvonne Beata , SCHMITT, Jeroen Antonius Johannes , BOSCHAT, Corina , HUDRY-LABBE, Julie , RIEKER, Claus
IPC分类号： A61K31/198 , A61K31/202 , A61K31/714 , A61P25/28
摘要： A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a nitric oxide releasing compound, and Vitamin B12. The composition is administered in a daily dose that provides 50 to 500 times the recommended daily requirement (RDA) of Vitamin B12 per day, for example about 200 times the RDA of Vitamin B12 per day. Optionally Vitamin B6 and/or Vitamin B9 can be included in the composition. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-β phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human.
摘要翻译：减轻，治疗或预防没有痴呆的个体的认知衰老的方法包括给予个体治疗有效量的含有ω-3脂肪酸，释放一氧化氮的组合物化合物和维生素B12。组合物以每日剂量施用，其提供维生素B12每日推荐每日需要量（RDA）的50至500倍，例如每天维生素B12的RDA约200倍。任选地，组合物中可包含维生素B6和/或维生素B9。该方法可以实现减少脑萎缩，增加或维持突触数量，增加淀粉样蛋白-β吞噬作用，或减少或维持非痴呆个体的神经炎症中的一种或多种益处。该方法可以预防有风险的个体，例如老年人的痴呆症。

5. 发明公开

EP3388061A1 OMEGA 3 FATTY ACIDS, NO RELEASING COMPOUND, VITAMIN B12 AND CHOLINE AS NEUROPROTECTANT IN PATIENTS WITH NO DEMENTIA 审中-公开
公开(公告)号：EP3388061A1
公开(公告)日：2018-10-17
申请号：EP17193916.8
申请日：2017-09-29
申请人： Nestec S.A.
发明人： RIEKER, Claus , HUDRY-LABBE, Julie , SCHMITT, Jeroen Antonius Johannes , BOSCHAT, Corina
IPC分类号： A61K31/198 , A61K31/202 , A61K31/714 , A61P25/28 , A61K31/14
CPC分类号： A61K31/202 , A61K31/14 , A61K31/198 , A61K31/714 , A61K2300/00
摘要： A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a nitric oxide releasing compound, Vitamin B12 and choline. The composition is administered in a daily dose that provides 0.1 to 50 times the recommended daily requirement (RDA) of Vitamin B12 per day, more preferably 0.1 to 40 times the recommended daily requirement (RDA) of Vitamin B12 per day and 0.01 to 10.0 times the recommended daily requirement (RDA) of choline. Optionally Vitamin B6 and/or Vitamin B9 can be included in the composition. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-β phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式